Cargando…
MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators
The use of peptides as drugs has progressed over time and continues to evolve as treatment paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has shown great promise for the treatment of muscle wasting diseases. Here, we report the MSTN-derived novel peptides MIF1 (10-...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031736/ https://www.ncbi.nlm.nih.gov/pubmed/35457038 http://dx.doi.org/10.3390/ijms23084222 |